Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
2seventy bio (TSVT)
NASDAQ:TSVT
2seventy bio (TSVT) Stock Price & Analysis
242 Followers
TSVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.54 - $12.69
Previous Close$4.52
Volume608.64K
Average Volume (3M)1.46M
Market Cap
$238.08M
Enterprise Value$247.62M
Total Cash (Recent Filing)$250.62M
Total Debt (Recent Filing)$260.16M
Price to Earnings (P/E)-1.0
Beta1.73
Next Earnings
May 09, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.41
Shares Outstanding51,311,132
10 Day Avg. Volume1,276,461
30 Day Avg. Volume1,458,178
Standard Deviation0.33
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.87
Price to Sales (P/S)4.29
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.52
Enterprise Value/Gross Profit7.52
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$12.00Price Target Upside165.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
2seventy bio News
PremiumCompany Announcements
2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma
PremiumCompany Announcements
2seventy bio Finalizes Asset Sale and Executive Transition
PremiumCompany Announcements
2seventy bio Reinforces Board, Faces Engine Capital Nominations
PremiumCompany Announcements
2seventy bio CSO Exits, Abecma Advances with FDA Committee
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst maintains a BUY rating with a $12 price target, indicating a belief in the stock's potential value.
Manufacturing ExpansionThe acute supply shortage for ABECMA will likely be alleviated with the addition of manufacturing facilities.
Regulatory ApprovalFDA approved ABECMA for use in earlier lines of therapy, expanding its market potential.
Bears Say
Company's OutlookThe company’s commercial outlook now hinges solely on Abecma, which is losing market share in the face of increasing competition.
Competitive RisksThe stock faces competitive risks, particularly from Carvykti, which may lead the market in BCMA CAR-T utilization.
Sales PressureSales of Abecma are currently under pressure from competitive therapies in the market.
---
Ownership Overview
48.63% Insiders
20.54% Mutual Funds
11.08% Other Institutional Investors
19.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TSVT FAQ
What was 2seventy bio’s price range in the past 12 months?
2seventy bio lowest stock price was $1.53 and its highest was $12.69 in the past 12 months.
What is 2seventy bio’s market cap?
Currently, no data Available
When is 2seventy bio’s upcoming earnings report date?
2seventy bio’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were 2seventy bio’s earnings last quarter?
2seventy bio released its earnings results on Mar 05, 2024. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$1.035 by -$0.075.
Is 2seventy bio overvalued?
According to Wall Street analysts 2seventy bio’s price is currently Undervalued.
Does 2seventy bio pay dividends?
2seventy bio does not currently pay dividends.
What is 2seventy bio’s EPS estimate?
2seventy bio’s EPS estimate is -$0.75.
How many shares outstanding does 2seventy bio have?
2seventy bio has 51,311,130 shares outstanding.
What happened to 2seventy bio’s price movement after its last earnings report?
2seventy bio reported an EPS of -$1.11 in its last earnings report, missing expectations of -$1.035. Following the earnings report the stock price went up 6.827%.
Which hedge fund is a major shareholder of 2seventy bio?
Among the largest hedge funds holding 2seventy bio’s share is Baker Bros Advisors LP. It holds 2seventy bio’s shares valued at 11M.
---
2seventy bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (165.49% Upside)
$12.00 (165.49% Upside)
Blogger Sentiment
Bullish
TSVT Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 253.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.84%
12-Months-Change
Fundamentals
Return on Equity
-76.91%
Trailing 12-Months
Asset Growth
-13.89%
Trailing 12-Months
Company Description
2seventy bio
2seventy bio Inc is primarely in the business of pharmaceutical preparations.
---
TSVT Earnings Call
Q4 2024
0:00 / 0:00
---
TSVT Stock 12 Months Forecast
Average Price Target
$12.00
▲(165.49% Upside)
Technical Analysis
Best Analysts Covering TSVT
1 Year
1 Year Success Rate
0/15 ratings generated profit
1 Year Average Return
-52.53%
reiterated a buy rating 2 months ago
Copying Daina Graybosch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.53% per trade.
---